Novavax Announces Management Promotions

GAITHERSBURG, Md., March 17, 2016 -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Dr. Gregory M. Glenn has been named President, Research & Development. Dr. Glenn joined Novavax as its Chief Scientific Officer in July 2010.  Previously, Dr. Glenn was Chief Scientific Officer and founder of IOMAI Corporation, acquired by Intercell in 2008. Dr. Glenn has 24 years of vaccine research development experience and has led the RSV program since 2010. He completed training in pediatrics at Madigan Army Medical Center, completed a Medical Research Fellowship at the Walter Reed Army Institute of Research, and conducted basic and clinical vaccine research at WRAIR before the founding of IOMAI.

Novavax also announced that Ms. Amy B. Fix has been named Senior Vice President, Regulatory Affairs and that Dr. Louis F. Fries III has been named Senior Vice President and Chief Medical Officer.

Ms. Fix joined Novavax in April 2013 as Vice President, Regulatory Affairs and is responsible for regulatory strategy, regulatory operations, and interactions with international regulatory agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency, and a number of other global regulatory agencies, which oversee the development and commercialization of Novavax vaccines. Prior to joining Novavax, Ms. Fix was Senior Director of Global Regulatory Affairs at Emergent Biosolutions after serving in Regulatory Affairs positions of increasing responsibility at a number of pharmaceutical companies, including Human Genome Sciences, Shire, MedImmune and Baxter.

Dr. Fries joined Novavax in 2011 with over 22 years of experience in clinical testing and development of human vaccines in academic, small biotech, and major biopharmaceutical environments. Dr. Fries’ extensive experience in infectious diseases, including influenza, bacterial and parasitic vaccines, and therapeutic and prophylactic immunoglobulins has lead to over 60 peer-reviewed publications. Prior to Novavax, Dr. Fries served as Director of Clinical Development from 2005 to 2011 of ID Biomedical (later acquired by GSK Biologicals. He has previously served in senior positions at Intellivax, Univax and Nabi and was a faculty member in the Department of International Health, at Johns Hopkins School of Hygiene and Public Health and trained in internal medicine at Johns Hopkins and infectious disease at the National Institutes of Allergy and Infectious Disease.

“Novavax’ accomplishments in 2015, including two End of Phase 2 meetings with the FDA leading to the initiation of two pivotal Phase 3 clinical trials of its RSV F Vaccine in the older adult and infant via maternal populations, were both historic and unprecedented. Greg, Amy and Lou were each instrumental leaders in these transformational activities,” said Stanley C. Erck, President and CEO. “Their collective expertise and experience will continue to lead Novavax in the coming months and years as we seek to bring our RSV F Vaccine to the global market. I am thrilled to congratulate Greg, Amy and Lou for their successes here at Novavax.”

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Contact: Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

[email protected] 
240-268-2000